Melinda Pruis

Melinda Pruis

Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing.

Back to news

More news

GenomeWeb: ‘Dutch Team Looks to Drug Repurposing to Improve Patient Outcomes, Lower Costs’

GenomeWeb: ‘Dutch Team Looks to Drug Repurposing to Improve Patient Outcomes, Lower Costs’

10-11-2016

The project is an attempt to address the rising healthcare costs associated with new cancer drugs and to identify biomarkers …

Update on the GENAYA Project: DNA from 500 Young Cancer Patients Analyzed

Update on the GENAYA Project: DNA from 500 Young Cancer Patients Analyzed

29-07-2025

Should young people with cancer receive different treatment than older patients? We suspect they do, but there’s currently not enough …

Oncoanalyser 3.0 for cancer genomics is out, now supporting Illumina, Ultima Genomics & Roche platforms

Oncoanalyser 3.0 for cancer genomics is out, now supporting Illumina, Ultima Genomics & Roche platforms

04-09-2026

Extensive work on the underlying WiGiTS tools now enable users to analyze sequencing data from three sequencing platforms (Illumina, Ultima …

Would you like to be kept up to date with new developments?

Sign up for our newsletters

Want to know more about the complete DNA test?

Visit OncoAct.nl